18+ Adults only. We do not sell to anyone under 18. Research compounds are supplied for research use only.
Hand holding a pre-filled injection pen, for the retatrutide half-life guide

Retatrutide half-life: about six days, and what that means

Retatrutide is injected once a week, and the reason is a single number: its half-life, which the first published human trial put at about six days. That one figure explains why a dose takes weeks to settle, why judging it after one injection tells you little, and why the level falls away slowly after the last one. This guide covers what the trial reported, what steady state means in plain terms, and where the number stops being useful.

Retatrutide half-life in 60 seconds

  • In the first published human trial, retatrutide had a half-life of approximately 6 days and dose-proportional pharmacokinetics.
  • That is why it is given once a week.
  • A weekly compound takes roughly four to five weeks to reach a steady level, so one or two injections show you very little.
  • After the last dose the level also falls slowly: about half is left after six days.
  • The figure comes from one early, Lilly-funded trial in adults with type 2 diabetes. Treat it as a guide, not a guarantee for any one person.

What the trial reported

The figure comes from a phase 1b trial published in The Lancet in 2022. It enrolled 72 adults with type 2 diabetes, who received once-weekly injections of retatrutide (then called LY3437943), a placebo or dulaglutide over 12 weeks. The doses ranged from 0.5mg up to a stepped schedule of 3, 6, 9 and 12mg.

The authors reported that the pharmacokinetics were dose proportional and that the half-life was approximately 6 days, which they said suggests suitability for once-weekly dosing. The most frequent side effects were gastrointestinal. Placebo-adjusted weight fell in a dose-dependent way, by up to about 9kg in the top group over 12 weeks.

Worth sitting with. This was a small, early, company-funded study in people with type 2 diabetes. It is the source for the half-life figure, not proof that the same number applies to everyone.

What half-life means

Half-life is the time it takes for half of a compound to be cleared from the blood. After one half-life, half is left. After two, a quarter. After five, about 3%. Our guide to peptide half-lives covers how long-acting peptides are engineered to last days instead of minutes.

Why steady state takes about a month

Each weekly dose lands on top of what is left of the last one. The level keeps building until the amount going in matches the amount being cleared. That point is steady state, and it takes roughly four to five half-lives to reach.

With a six day half-life and a dose every seven days, simple arithmetic gives the picture below. It is an illustration built from the six day figure, assuming the simplest possible model, and not data from the trial.

What this means in practice

  • Do not judge a dose after one or two injections. The level is still climbing. This is part of why the large GLP-1 trials stepped the dose up every four weeks, covered in why GLP-1 doses start low.
  • A dose change takes about a month to show its full effect, for the same reason.
  • A missed or late dose fades slowly. Because the level falls by half over about six days, one late injection is a gentle dip, not a cliff.
  • After the last dose the level falls just as slowly. About half is left after six days, and after five half-lives, about a month, only about 3% remains.

What the half-life does not tell you

Half-life is about the level in the blood. It does not tell you how long the effects last, which can outlast the level, and it does not predict side effects. It also came from a single early trial in a specific group of people, so treat it as approximately six days rather than exactly six days. For how the effects unfolded over time in the larger phase two trial, see retatrutide week by week. For food, training and sleep while on a weekly compound, see how to get more from retatrutide.

Retatrutide half-life: questions

What is the half-life of retatrutide?

In the phase 1b trial published in The Lancet in 2022, the half-life was approximately 6 days, with dose-proportional pharmacokinetics, in adults with type 2 diabetes.

Why is retatrutide taken once a week?

Because a half-life of about six days keeps the level in the blood from falling away quickly between doses. The trial authors said the pharmacokinetics suggest suitability for once-weekly dosing.

How long does retatrutide take to reach steady state?

Roughly four to five half-lives, which with a six day half-life is about four to five weekly doses. That is simple arithmetic from the half-life figure, not a number reported in the trial.

How long does retatrutide stay in your system after the last dose?

With a half-life of about six days, about half is left after six days and about 3% after roughly a month. This is arithmetic from the half-life figure, and individual results will vary.

Is retatrutide approved?

No. It is still investigational and is not approved by SAHPRA or any other regulator. Everything we supply is for research use only.

Sources

  • Urva S et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. The Lancet, 2022;400(10366):1869-1881. doi.org/10.1016/S0140-6736(22)02033-502033-5) (PubMed 36354040).

Everything we supply is for research use only and is not a registered medicine. Nothing here is medical advice.

Keep reading: retatrutide vs tirzepatide vs semaglutide, retatrutide in South Africa and peptide half-lives explained.